Список проголосовавших за комментарий " <table class="BriefingDataTable" border="0" cellspacing="0" cellpadding="0"><tr> <td class="tickerColumn"> </td> <td class="articleColumn">Tetraphase Pharmaceuticals target raised to $7 at Stifel; Hold (6.20)Stifel raises their TTPH tgt to $7 from $5 as they continue to find TTPH shares increasingly interesting ahead of YE17 P3 IGNITE4 data and FY17 P1 data read-outs for pipeline assets, which they believe could prove longer-term sources of additional value (particularly TP-6076). Firm acknowledges the prospect of complicated intra-abdominal infections (cIAI) as a standalone indication for IV eravacycline isn't likely to meaningfully shift investor enthusiasm into overdrive. However, they view potentially positive IGNITE4 data as an important de-risking event, which should increase anticipation around P3 IGNITE3 data in complicated urinary tract infections (cUTI) — the much larger gram-negative indication in which the once-daily (QD) dosing profile of IV eravacycline and specific pathogen coverage can better serve as a point of competitive differentiation. <strong>They view any positive update on the viability of an oral eravacycline formulation (expected 3Q17) as another potential source of longer-term upside unaccounted for in their model.</strong></td> </tr></table>"